Icosavax pushes forward combo RSV-hMPV vaccine and announces direct stock offering
Seattle-based Icosavax may have failed in its attempt at a Covid-19 vaccine in 2022, but it released early data on its bivalent vaccine candidate for RSV and human metapneumovirus (hMPV) — and announced a $67.8 million direct offering of its common stock yesterday.
The vaccine candidate for older adults, dubbed IVX-A12 and granted fast track designation by the FDA, is made up of the company’s RSV and hMPV vaccines. The bivalent vaccine could potentially take meaningful market share in a future ~$10 billion+ market.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.